Direct compression of fluconazole IP/USP/EP/BP into conventional immediate-release tablets is conducted with a pre-blend containing microcrystalline cellulose, dibasic calcium phosphate anhydrous, croscarmellose sodium, povidone, and magnesium stearate; the active pharmaceutical ingredient is first passed through a 0.5 mm conical mill to break up loosely adherent agglomerates and improve blend uniformity. A 150 mg tablet with a 300 mg core corresponds to 50.0% w/w drug loading, while a 200 mg tablet with a 430 mg core corresponds to approximately 46.5% w/w; for lower-dose 50 mg tablets, the API fraction may fall to 15–20% w/w when a 250–330 mg core is retained for patient acceptability. Final blend lubricant level is maintained at 0.25–1.0% w/w and mixing time is limited to 3–5 minutes in a diffusion or V-blender to avoid over-lubrication. Compression is performed on a 27-station rotary tablet press with compaction force held between 8 kN and 18 kN, producing hardness from 5 kp to 12 kp and friability below 1.0% as tested per USP <1216>. Tablet weight, thickness, and hardness are sampled at intervals of not more than 15 minutes; press speed is typically 30–60 rpm for 12 mm round tooling, but the exact speed is adjusted to maintain pre-compression dwell time and avoid capping at high drug load.

Compliance for immediate-release fluconazole tablets is anchored to the USP/NF monograph, which specifies HPLC assay and dissolution using USP <711> Apparatus 2 at 50 rpm in 900 mL of water, with a Q value of not less than 80% at 30 minutes. Content uniformity must meet USP <905>, and disintegration is controlled by USP <701> with a limit of not more than 15 minutes in water at 37°C. The oral solid-dose manufacturing suite is operated under 21 CFR 210 and 211, with residual solvents controlled by ICH Q3C, elemental impurities by ICH Q3D, and microbiological acceptance criteria for non-sterile products per USP <61> and <62>. The terminal finished product is a film-coated immediate-release tablet at 50 mg, 100 mg, 150 mg, or 200 mg; aqueous film coating is applied in a perforated pan coater at 0.5–2.0% w/w weight gain to reduce dusting and improve swallowability.

How Does Monograph-Grade Fluconazole Remain Uniformly Suspended in 40 mg/mL Dry Syrup Systems?

Powder for oral suspension is a dry blend of fluconazole with sucrose, sodium citrate dihydrate, anhydrous citric acid, sodium benzoate, titanium dioxide, colloidal silicon dioxide, and xanthan gum; the dry powder is filled into HDPE bottles with a desiccant canister and sealed with a child-resistant closure. For a 35 g dry powder containing 1400 mg fluconazole, the API loading is 4.0% w/w, and reconstitution to 35 mL with purified water yields a 40 mg/mL suspension. The 10 mg/mL presentation, equivalent to 50 mg/5 mL, follows a proportionally lower dry-powder mass per bottle. Sodium benzoate concentration is maintained at 0.1–0.2% w/w of the reconstituted liquid and requires preservative effectiveness testing under USP <51>. Xanthan gum is dispersed in the dry powder to avoid fish-eye formation upon initial hydration; the gum hydrates rapidly when the bottle is shaken with 23–27°C purified water.

Manufacturing is conducted in a humidity-controlled suite at or below 40% RH because sucrose-based blends develop flow instability above 45% RH. Dry blending is performed in a ribbon or V-blender, with API added by geometric dilution; the final blend is sampled for content uniformity at 10 locations before volumetric filling. In-process checks include fill weight by weight/volume correlation on a minimum of 10 bottles per fill head, sieve cut for agglomerates using 0.850 mm mesh, and loss on drying below 2.0%. The terminal finished product is a powder for oral suspension producing 50 mg/5 mL or 200 mg/5 mL after reconstitution, stored below 30°C and used within 14 days after purified water is added. Compliance includes the pharmacopoeial monograph for fluconazole for oral suspension, USP <61> and <62>, USP <698> for deliverable volume, and ICH Q3C for residual solvent control.

Aseptic Processing of Fluconazole 2 mg/mL Intravenous Infusion Solution

Fluconazole for intravenous infusion is supplied as a solution at a concentration of 2 mg/mL, equivalent to 0.2% w/v, in 0.9% sodium chloride or 5% dextrose; a 100 mL container therefore contains 200 mg fluconazole, and a 200 mL container contains 400 mg. The API is dissolved in water for injection at 20–25°C with gentle agitation, and the pH is adjusted with dilute hydrochloric acid or sodium hydroxide to the range 4.0–8.0. The solution is passed through 0.45 µm prefiltration and 0.22 µm sterilizing-grade polyethersulfone or polyvinylidene fluoride membrane filters before aseptic filling into presterilized PVC-free polyolefin bags or glass bottles. Terminal sterilization may be validated as an alternative for selected container types only after confirming that pH drift and related substances remain within the pharmacopoeial monograph; published data for terminal sterilization of all container configurations is limited.

Process controls focus on filter integrity by bubble point or diffusion flow before and after filtration, fill volume accuracy per USP <1> injections, bacterial endotoxins per USP <85>, sterility per USP <71>, particulate matter per USP <788> and Ph. Eur. 2.9.19, and visible particulates per USP <790>. The finished product type is a ready-to-use intravenous infusion in 100 mL or 200 mL presentations for slow infusion; it is not formulated for bolus administration, and the infusion rate should not exceed 5 mg/min unless otherwise justified by a prescriber. Container-closure compatibility requires elastomeric closures free of natural rubber latex and aluminum overseals with tamper evidence; in-process leak testing is performed by vacuum decay on every container after capping.

Encapsulation of fluconazole into hard gelatin or hydroxypropyl methylcellulose shells is performed with a dry blend of lactose monohydrate or microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate; fill weight is typically between 220 mg and 380 mg for 50 mg to 200 mg doses, placing API content between 20% and 55% w/w depending on shell size and excipient bulk density. Because fluconazole is a relatively free-flowing crystalline powder, short mixing times and low lubricant levels are used to preserve powder flow and prevent weight sorting in the dosing disc. Encapsulation is run on dosator or tamping-pin machines at 40–55% RH, with fill weight verification every 15 minutes and in-process disintegration tested on finished capsules. The operating boundary is stricter for gelatin shells, which must be kept below 50% RH to avoid pellicle cross-linking that slows release; HPMC shells are selected when stability zones above 50% RH are anticipated.

Dissolution release is verified with the paddle conditions set in the capsule monograph—900 mL water at 50 rpm and Q not less than 80% at 30 minutes—but the shell must first pass USP <701> disintegration, because pellicle cross-linking can delay release independently of blend performance. Content uniformity must meet USP <905>, and the fill material is tested for microbial limits under USP <61> and <62>. Residual solvents and elemental impurities are controlled under ICH Q3C and Q3D, and batch release follows 21 CFR 210 and 211. The terminal finished product is a hard capsule in 50 mg, 100 mg, 150 mg, or 200 mg strengths for oral administration, filled into blisters with desiccant when high-humidity stability zones are targeted.

When Fluconazole Oral Granules Are Packed into Unit-Dose Sachets

Fluconazole oral granules are manufactured by wet granulation when a sachet presentation is intended, because the granular matrix improves flow into sachet dosing systems and reduces fugitive dust in the packaging suite. A representative 1 g sachet containing 50 mg fluconazole corresponds to 5.0% w/w API loading; a 1.5 g sachet containing 100 mg fluconazole corresponds to approximately 6.7% w/w. The binding solution consists of povidone K30 at 2–5% w/w of the dry granule mass dissolved in purified water, added in a high-shear granulator at an impeller speed of 200–250 rpm for 3–4 minutes. The wet mass is dried in a fluid-bed dryer with inlet air temperature controlled at 55–65°C until loss on drying is less than 2.0%, followed by sizing through a 1.0 mm oscillating granulator; granules outside the 0.250–1.000 mm range are milled or discarded to maintain dissolution consistency.

Oral granules are blended with a glidant before filling into single-dose sachets on a vertical form-fill-seal line with a fill weight accuracy of ±5% and sealing temperature validated for the laminate structure. In-process control includes moisture content after drying, granule size distribution, and bulk/tapped density measured by USP <616>. Compliance includes the oral powder/granule monograph where available, USP <905> for uniformity of dosage units, USP <61> and <62>, and ICH Q3C for residual solvents. The terminal product is a single-dose granule sachet at 50 mg or 100 mg that is dispersed in 5–10 mL of water before administration or given by nasogastric tube as prescribed.

Dispersible Tablet Production Modifies Disintegration Kinetics Below 3 Minutes

Dispersible tablets of fluconazole are formulated with a dual disintegrant system of crospovidone and sodium starch glycolate at a combined level of 6–12% w/w, with microcrystalline cellulose and mannitol or lactose as the diluent skeleton. A 50 mg dose in a 250 mg tablet corresponds to 20.0% w/w API loading, and a 100 mg dose in a 400 mg tablet corresponds to 25.0% w/w; the lubricant is magnesium stearate at 0.5–1.0% w/w, blended for no longer than 3 minutes to avoid excessive hydrophobicity. Tablets are compressed to hardness 4–7 kp, which balances friability below 1.0% against a disintegration time of less than 3 minutes in water at 25°C when tested per USP <701> or Ph. Eur. 2.9.1. Compression is normally performed on a rotary press with pre-compression; capping is a batch failure mode when the compression speed exceeds the plastic deformation capacity of mannitol-based granules.

The production process for dispersible tablets generally uses wet granulation to improve content uniformity at low dose strengths, though direct compression can be employed if the API particle size and blend segregation are controlled. After compression, tablets are filled into aluminum/aluminum blisters or HDPE bottles with desiccant, because moisture uptake above 60% RH can increase disintegration time; packaging suites are maintained at or below 55% RH during filling. The terminal finished product is a dispersible tablet in 50 mg or 100 mg strengths, intended to be dispersed in 5–10 mL of water to form a homogeneous suspension at the point of administration. Compliance includes the pharmacopoeial monograph for dispersible tablets where available, USP <905> for content uniformity, USP <61> and <62>, ICH Q3C for residual solvents, and 21 CFR 210 and 211 for manufacturing controls.